NOW FDA-APPROVED FOR A NEW FIRST-LINE MAINTENANCE USE

After responding to platinum-based chemotherapy

LYNPARZA + bevacizumab may give women with HRD-positive advanced ovarian cancer MORE TIME without their cancer growing or returning compared to bevacizumab.*

*LYNPARZA + bevacizumab was studied against bevacizumab + placebo.

Talk to your doctor about a test to see if LYNPARZA is right for you

Ask your doctor about an HRD test to see if LYNPARZA + bevacizumab is right for you.

The PAOLA-1 study evaluated advanced ovarian cancer patients who received LYNPARZA + bevacizumab after responding to platinum-based chemotherapy and bevacizumab. The results presented are a subset of the LYNPARZA PAOLA-1 study and should be discussed with your doctor. In the subset of 387 women with HRD-positive advanced ovarian cancer, 255 women received LYNPARZA + bevacizumab and 132 women received bevacizumab + placebo.

WOMEN RECEIVING LYNPARZA + BEVACIZUMAB DID NOT SEE THEIR HRD-POSITIVE ADVANCED OVARIAN CANCER GROW OR RETURN FOR A MEDIAN OF OVER 3 YEARS (37.2 MONTHS) COMPARED TO 17.7 MONTHS FOR WOMEN ON BEVACIZUMAB + PLACEBO.*

LYNPARZA + bevacizumab lowered the risk of disease progression or death by 67% compared to bevacizumab. 168 out of 255 women on LYNPARZA + bevacizumab did not see their cancer grow or return compared to 40 out of 132 women on bevacizumab + placebo.*

*Because of the design of this study, the statistical meaning of these results may be limited. Talk to your doctor to see if LYNPARZA + bevacizumab is right for you

An HRD Test Can Help Determine if LYNPARZA + bevacizumab is Right For You

Talk to your doctor about an HRD test icon

HRD* is an important biomarker of advanced ovarian cancer. An HRD test assesses the DNA profile of your tumor, including different mutations and other changes to your DNA. Approximately half of these are BRCA mutations, so even if you are BRCA-negative you could still be HRD-positive.

HRD might be more common than you think

~50% of women with advanced ovarian cancer test positive for HRD.

Knowing your HRD status as early as possible may determine whether LYNPARZA + bevacizumab is a treatment option for you.

*Homologous recombination deficiency.

Talk to your doctor about an HRD test icon

Ask Your Doctor About Combination Maintenance Therapy

LYNPARZA + bevacizumab: two proven medicines, one new combination

Talk to your doctor about genetic testing

Your doctor may prescribe your initial platinum-based chemotherapy treatment on its own or in combination with bevacizumab. Once you have responded to chemotherapy, your doctor may prescribe LYNPARZA + bevacizumab as maintenance therapy.

Maintenance Therapy May Make A Difference

Working with your doctor can give you the reassurance that you are considering all of your options. Together you can go through the possibilities and decide on a unique treatment plan for you.

You’ll most likely discuss the following steps, including maintenance therapy, which may help prevent your advanced ovarian cancer from growing or returning.

CONSIDERATIONS FOR FIRST-LINE TREATMENT PLAN

Testing

Tests are used to confirm diagnoses and help create a treatment plan.

Your doctor can test for BRCA and HRD*, which are important biomarkers in advanced ovarian cancer and can help inform what therapies may work for you.

Surgery

Your doctor will discuss your surgical options and whether surgery is right for you.

Chemotherapy

Chemotherapy may be prescribed before or after surgery. It can be used on its own or in combination with other therapies.

Maintenance therapy

Maintenance therapy may help preserve the progress you achieved on chemotherapy.

Your doctor may recommend maintenance therapy using certain treatments in combination or on their own.

TALK TO YOUR DOCTOR ABOUT INCLUDING MAINTENANCE THERAPY IN YOUR FIRST-LINE TREATMENT PLAN

*Homologous recombination deficiency.

Patient Support

AstraZeneca Access 360

AstraZeneca Access 360TM

Helps you access the care you need

If your doctor has prescribed LYNPARZA, you may have questions. The AstraZeneca Access 360TM program can help. We can answer your questions about insurance coverage, out-of-pocket costs, and patient assistance programs. To learn more about the Access 360 program, please call 1-844-ASK-A360 (1-844-275-2360)1-844-ASK-A360 (1-844-275-2360) Monday - Friday, 8 AM - 8 PM EST, or visit www.MyAccess360.com.

LYNPARZA $0 co-pay

AstraZeneca strives to make LYNPARZA affordable by targeting a $0 co-pay for all eligible patients.

This is based on commercially insured patients. The average monthly cost for LYNPARZA may be greater than $0 for some patients.

LYNPARZA support hotline

Support Hotline

If you have any questions about LYNPARZA, speak with one of our specially trained nurses.
To speak with a nurse, call 1-800-770-8337call 1-800-770-8337.

How to take LYNPARZA + bevacizumab

Take LYNPARZA exactly as your doctor tells you. Two tablets (300 mg per dose), twice a day, totaling four tablets each day by mouth (600 mg daily dose). Bevacizumab is targeted therapy, not chemotherapy.

How to take LYNPARZA

2 TABLETS IN THE MORNING(300 mg)

+
How to take LYNPARZA

2 TABLETS IN THE EVENING(300 mg)

Take doses 12 hours apart with or without food.

Images do not represent the actual size of the tablets.

Bevacizumab infusion

BEVACIZUMAB EVERY 3 WEEKS(15 mg/kg)

Your doctor will determine how long you receive LYNPARZA + bevacizumab as maintenance therapy.

Important things to keep in mind when taking LYNPARZA

  • You should take LYNPARZA exactly as your doctor tells you
  • Swallow the tablets whole—do not chew, crush, dissolve, or divide them
  • Take each dose about 12 hours apart, with or without food
  • Do not take more than 4 tablets a day
  • Do not change your dose or stop taking LYNPARZA unless your doctor tells you to
  • Your doctor may temporarily stop treatment with LYNPARZA or change your dose of LYNPARZA if you experience side effects

Each treatment plan is unique and any questions you might have should be discussed with your doctor.

Foods to avoid Avoid grapefruit, grapefruit juice, Seville oranges and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.

If you miss a doseTake your next dose at the usual scheduled time. Do not take an extra dose to make up for the one you missed.

If you take too muchCall your doctor or go to the nearest hospital emergency room right away.

Downloadable resources

LYNPARZA patient information

Learn about how to take LYNPARZA + bevacizumab, data from clinical trials, side effects, and dosing information

DOWNLOAD
LYNPARZA Patient Brochure

Tips for managing your treatment

Learn more about the potential side effects of LYNPARZA and how you should work with your doctor to manage them.

DOWNLOAD
Tips for Managing Your Treatment Brochure

LYNPARZA caregivers

Our Caregiver Brochure provides useful tips and information. Learn more about the importance of looking after yourself as a caregiver.

DOWNLOAD
LYNPARZA Caregiver Brochure

My LYNPARZA support

Education and support may help make a meaningful difference.

Registration

Sign up forMy LYNPARZA Support Program

MyLYNPARZA is a support program that is unique to your treatment journey. We developed this program with one goal in mind: to be there for you and your loved ones.

*Required fields.

An error has occurred. Please make sure you have correctly filled out the highlighted fields.

 
 
 
 
 
 
 I am a patient taking LYNPARZA
 I care for someone taking LYNPARZA
 I would like to receive information about relevant AstraZeneca products, programs and services that may be of interest to me.
 I would like to receive the MyLYNPARZA treatment journal.
 1
 
 
 
 
 

By clicking SUBMIT, you are certifying that you or the individual you are signing up is 18 years or older and agrees to receive information from AstraZeneca about programs and services related to LYNPARZA.

We protect your information. AstraZeneca respects your personal health information. The information you provide may be used to send you health-related materials and to develop products, services, and programs. AstraZeneca, or third parties working on our behalf, will not sell or rent personal health information. If, in the future, you no longer want to receive health-related materials, call 1-800-236-9933. call 1-800-236-9933. Please visit www.azprivacynotice.com to review our Privacy Notice.


THANKS FOR JOINING MYLYNPARZA

Your submission was successful.

IMPORTANT SAFETY INFORMATION

WHAT IS LYNPARZA?

LYNPARZA is a prescription medicine used to treat adults who have:

  • advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of abnormal BRCA gene or a positive laboratory tumor test for genomic instability called HRD. LYNPARZA is used in combination with another anti-cancer medicine, bevacizumab, as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that LYNPARZA is right for you

It is not known if LYNPARZA is safe and effective in children.

IMPORTANT SAFETY INFORMATION

LYNPARZA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.

Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.

Your healthcare provider will do blood tests to check your blood cell counts:

  • before treatment with LYNPARZA
  • every month during treatment with LYNPARZA
  • weekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with LYNPARZA until your blood cell counts improve

Lung problems (pneumonitis). Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis. Pneumonitis may lead to death.

Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:

  • have lung or breathing problems
  • have kidney problems
  • are pregnant, become pregnant, or plan to become pregnant. LYNPARZA can harm your unborn baby and may cause loss of pregnancy (miscarriage)
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with LYNPARZA
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with LYNPARZA and for 6 months after the last dose of LYNPARZA. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you might be pregnant following treatment with LYNPARZA
  • are breastfeeding or plan to breastfeed. It is not known if LYNPARZA passes into your breast milk. Do not breastfeed during treatment with LYNPARZA and for 1 month after receiving the last dose of LYNPARZA. Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.

How should I take LYNPARZA?

  • Take LYNPARZA tablets exactly as your healthcare provider tells you
  • Do not change your dose or stop taking LYNPARZA unless your healthcare provider tells you to. Your healthcare provider may temporarily stop treatment with LYNPARZA or change your dose of LYNPARZA if you experience side effects
  • Your healthcare provider will decide how long you stay on treatment
  • Do not take more than 4 LYNPARZA tablets in 1 day. If you have any questions about LYNPARZA, talk to your healthcare provider or pharmacist
  • Take LYNPARZA by mouth 2 times a day
  • Each dose should be taken about 12 hours apart
  • Swallow LYNPARZA tablets whole. Do not chew, crush, dissolve, or divide the tablets
  • Take LYNPARZA with or without food
  • If you miss a dose of LYNPARZA, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose
  • If you take too much LYNPARZA, call your healthcare provider or go to the nearest hospital emergency room right away

What should I avoid while taking LYNPARZA?

Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.

LYNPARZA may cause serious side effects (see above). The most common side effects of LYNPARZA are:

  • nausea or vomiting. Tell your healthcare provider if you get nausea or vomiting. Your healthcare provider may prescribe medicines to treat these symptoms
  • tiredness or weakness
  • low red blood cell counts
  • diarrhea
  • loss of appetite
  • headache
  • low white blood cell counts
  • changes in the way food tastes
  • cough
  • shortness of breath
  • dizziness
  • indigestion or heartburn
  • low platelet counts
  • upper stomach area (abdominal) pain

These are not all the possible side effects of LYNPARZA. Call your healthcare provider for medical advice about side effects.

You may report side effects related to AstraZeneca products by clicking here. If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Please click here for complete Prescribing Information, including Patient Information (Medication Guide).

IMPORTANT SAFETY INFORMATION

Read More

LYNPARZA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.